Control of gluconeogenesis by metformin: does redox trump energy charge?

Baur, Joseph A; Birnbaum, Morris J · Cell Metab · 2014

editorial · Level V

Where this comes from

Abstract

Metformin is the most widely prescribed drug to lower glucose in type II diabetics, yet its mechanism of action remains controversial. A new study reveals that metformin inhibits mitochondrial glycerol-3-phosphate dehydrogenase, triggering reduction of the cytosolic NADH/NAD(+) pool and impaired utilization of redox-dependent substrates for gluconeogenesis (Madiraju et al., 2014).

Medical subject headings